STUDY OBJECTIVE: To test the hypothesis that genotypes for proteins affecting vitamin K availability influence the duration of time required to achieve a stable warfarin dose in African-American patients. DESIGN: Retrospective cohort study. SETTING: Pharmacist-managed antithrombosis clinic. PATIENTS: Ninety-two African-American adults whose warfarin therapy was initiated between September 2, 1999, and July 8, 2009. MEASUREMENTS AND MAIN RESULTS: During a routine anticoagulation clinic visit, a sample was collected from each patient for genetic analysis. genotyping was performed for the following variants: apolipoprotein E ε2, ε3, and ε4; NAD(P)H:quinone oxidoreductase (NQO1)*2; cytochrome P450 (CYP) 4F2 V433M; CYP2C9*2, *3, *5, *8, and *11; and vitamin K epoxide reductase complex 1 (VKORC1) -1639G>A. Patients' medical records were then reviewed, and data were collected retrospectively for each anticoagulation clinic visit during the first 6 months of warfarin therapy or until dose stabilization. The median time required to reach a stable warfarin dose, defined as the dose that produced therapeutic anticoagulation for three consecutive clinic visits, was 83 days. Compared with the 46 patients who achieved a stable warfarin dose within 83 days, the 46 patients who required longer durations for dose stabilization had a higher frequency of the apolipoprotein E ε3/ε3 genotype (37% vs 59%, p=0.037). Sixty-one percent of patients with the ε3/ε3 genotype versus 40% of those with an ε2 or ε4 allele had a delay in achieving a stable dose (p=0.037). Neither the CYP4F2 nor NQO1 genotype was associated with warfarin dose stabilization. CONCLUSION: Our data support the hypothesis that the apolipoprotein E genotype is associated with duration of time to reach a stable warfarin dose in African-American patients. Further insight into the genetic effects on warfarin dose stabilization could reveal novel methods to improve anticoagulation control during the warfarin initiation period.
STUDY OBJECTIVE: To test the hypothesis that genotypes for proteins affecting vitamin K availability influence the duration of time required to achieve a stable warfarin dose in African-American patients. DESIGN: Retrospective cohort study. SETTING: Pharmacist-managed antithrombosis clinic. PATIENTS: Ninety-two African-American adults whose warfarin therapy was initiated between September 2, 1999, and July 8, 2009. MEASUREMENTS AND MAIN RESULTS: During a routine anticoagulation clinic visit, a sample was collected from each patient for genetic analysis. genotyping was performed for the following variants: apolipoprotein E ε2, ε3, and ε4; NAD(P)H:quinone oxidoreductase (NQO1)*2; cytochrome P450 (CYP) 4F2V433M; CYP2C9*2, *3, *5, *8, and *11; and vitamin K epoxide reductase complex 1 (VKORC1) -1639G>A. Patients' medical records were then reviewed, and data were collected retrospectively for each anticoagulation clinic visit during the first 6 months of warfarin therapy or until dose stabilization. The median time required to reach a stable warfarin dose, defined as the dose that produced therapeutic anticoagulation for three consecutive clinic visits, was 83 days. Compared with the 46 patients who achieved a stable warfarin dose within 83 days, the 46 patients who required longer durations for dose stabilization had a higher frequency of the apolipoprotein E ε3/ε3 genotype (37% vs 59%, p=0.037). Sixty-one percent of patients with the ε3/ε3 genotype versus 40% of those with an ε2 or ε4 allele had a delay in achieving a stable dose (p=0.037). Neither the CYP4F2 nor NQO1 genotype was associated with warfarin dose stabilization. CONCLUSION: Our data support the hypothesis that the apolipoprotein E genotype is associated with duration of time to reach a stable warfarin dose in African-American patients. Further insight into the genetic effects on warfarin dose stabilization could reveal novel methods to improve anticoagulation control during the warfarin initiation period.
Authors: Y Liu; H Jeong; H Takahashi; K Drozda; S R Patel; N L Shapiro; E A Nutescu; L H Cavallari Journal: Clin Pharmacol Ther Date: 2012-02-29 Impact factor: 6.875
Authors: W Hernandez; E R Gamazon; K Aquino-Michaels; S Patel; T J O'Brien; A F Harralson; R A Kittles; A Barbour; M Tuck; S D McIntosh; J N Douglas; D Nicolae; L H Cavallari; M A Perera Journal: Pharmacogenomics J Date: 2013-09-10 Impact factor: 3.550
Authors: W Hernandez; E R Gamazon; K Aquino-Michaels; E Smithberger; T J O'Brien; A F Harralson; M Tuck; A Barbour; L H Cavallari; M A Perera Journal: J Thromb Haemost Date: 2017-03-25 Impact factor: 5.824
Authors: Larisa H Cavallari; Minoli Perera; Mia Wadelius; Panos Deloukas; Gelson Taube; Shitalben R Patel; Keston Aquino-Michaels; Marlos A G Viana; Nancy L Shapiro; Edith A Nutescu Journal: Pharmacogenet Genomics Date: 2012-02 Impact factor: 2.089
Authors: Brian S Finkelman; Benjamin French; Luanne Bershaw; Stephen E Kimmel Journal: Pharmacoepidemiol Drug Saf Date: 2014-12-11 Impact factor: 2.890
Authors: Edith A Nutescu; Katarzyna Drozda; Adam P Bress; William L Galanter; James Stevenson; Thomas D Stamos; Ankit A Desai; Julio D Duarte; Victor Gordeuk; David Peace; Shrihari S Kadkol; Carol Dodge; Santosh Saraf; John Garofalo; Jerry A Krishnan; Joe G N Garcia; Larisa H Cavallari Journal: Pharmacotherapy Date: 2013-07-17 Impact factor: 4.705